Hanmi's New Story
Soaring Towards a
Shared Future,
Unveiling
a New Chapter of Hanmi
Meet Us at 2025 ASCO GI Cancers Symposium.
A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer
- Poster Number
- 426
- Session
- Jan 23 at 11:30~1:00 PM, Poster Board #E16
- Presenter
-
Do-Youn Oh, M.D., Ph.D. / Seoul National University Hospital,
Paul (DongJun) Rhee, Ph.D. / Hanmi Pharmaceutical
Meet Us at WORLD Symposium 2025.
Beneficial effects of HM15421, a novel long-acting alpha-galactosidase A analog, following a switch from the conventional enzyme replacement therapy in a symptomatic Fabry mouse model
- Poster Number
- LB-22
- Session
- Feb 4 at 15:30~17:30 PM, Exhibit Hall (Seaport Ballroom)
- Presenter
-
Cho Rong Park, Ph.D. /
Hanmi Pharmaceutical
A novel long-acting alpha-galactosidase A analog, HM15421, mitigates progressive renal impairment in Fabry disease via enhanced renal targeting and prolonged cellular retention
- Poster Number
- LB-41
- Session
- Feb 5 at 15:30~17:30 PM, Exhibit Hall (Seaport Ballroom)
- Presenter
-
Cho Rong Park, Ph.D. /
Hanmi Pharmaceutical
Comparative efficacy of conventional ERT drugs and HM15421, a novel long-acting alpha-galactosidase A analog, in a symptomatic Fabry mouse model
- Poster Number
- LB-24
- Session
- Feb 4 at 15:30~17:30 PM, Exhibit Hall (Seaport Ballroom)
- Presenter
- Wonki Kim, Ph.D. / Hanmi Pharmaceutical
